Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Sutro Biopharma Inc (STRO)
NASDAQ:STRO
Holding STRO?
Track your performance easily
STRO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.67 - $6.13
Previous CloseN/A
Volume326.60K
Average Volume (3M)1.24M
Market Cap
$152.55M
Enterprise Value$92.45M
Total Cash (Recent Filing)$47.52M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta2.81
Next Earnings
Mar 26, 2025EPS Estimate
-0.83Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.62
Shares Outstanding82,458,725
10 Day Avg. Volume850,607
30 Day Avg. Volume1,238,297
Standard Deviation0.20
R-Squared0.09
Alpha-0.02
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)0.94
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap0.61
Enterprise Value/Revenue0.57
Enterprise Value/Gross Profit0.60
Enterprise Value/Ebitda-1.15
Forecast
1Y Price Target
$10.50Price Target Upside467.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Sutro Biopharma News
PremiumCompany Announcements
Sutro Biopharma Advances Pipeline Amid Financial Losses
Bulls Say, Bears Say
Bulls Say
Clinical Trials And Treatment PotentialSutro initiated a Phase 2 trial for luvelta in NSCLC after a recent IND clearance, with initial data expected in 2025.
Financial PositionMultiple partners are providing non-dilutive capital, and the company has a solid cash position of $388.3MM.
Partnerships And CollaborationsThe company’s strong track record of securing collaborations, such as its recent Ipsen partnership for STRO-003 (ROR1-ADC), supports the potential for further deals.
Bears Say
Financial PerformanceThere is a ~42% potential downside with a bear case price of $2.
Pipeline And CatalystsShares are down -13% YTD vs. XBI's +11% largely because of the lack of pipeline catalysts.
Product Development DelaysThe potential launch timing for Luvelta seems to be pushed to 2028, which may be why shares are weak on the update.
---
Ownership Overview
8.83% Insiders
10.58% Mutual Funds
0.02% Other Institutional Investors
69.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
STRO FAQ
What was Sutro Biopharma Inc’s price range in the past 12 months?
Sutro Biopharma Inc lowest stock price was $1.67 and its highest was $6.13 in the past 12 months.
What is Sutro Biopharma Inc’s market cap?
Sutro Biopharma Inc’s market cap is $152.55M.
When is Sutro Biopharma Inc’s upcoming earnings report date?
Sutro Biopharma Inc’s upcoming earnings report date is Mar 26, 2025 which is in 67 days.
How were Sutro Biopharma Inc’s earnings last quarter?
Sutro Biopharma Inc released its earnings results on Nov 13, 2024. The company reported -$0.59 earnings per share for the quarter, beating the consensus estimate of -$0.735 by $0.145.
Is Sutro Biopharma Inc overvalued?
According to Wall Street analysts Sutro Biopharma Inc’s price is currently Undervalued.
Does Sutro Biopharma Inc pay dividends?
Sutro Biopharma Inc does not currently pay dividends.
What is Sutro Biopharma Inc’s EPS estimate?
Sutro Biopharma Inc’s EPS estimate is -0.83.
How many shares outstanding does Sutro Biopharma Inc have?
Sutro Biopharma Inc has 82,458,725 shares outstanding.
What happened to Sutro Biopharma Inc’s price movement after its last earnings report?
Sutro Biopharma Inc reported an EPS of -$0.59 in its last earnings report, beating expectations of -$0.735. Following the earnings report the stock price went down -12.879%.
Which hedge fund is a major shareholder of Sutro Biopharma Inc?
Currently, no hedge funds are holding shares in STRO
---
Sutro Biopharma Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$10.50 (467.57% Upside)
$10.50 (467.57% Upside)
Blogger Sentiment
Bullish
STRO Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 422.0K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.7%
Last 30 Days ▼ 2.0%
Last 30 Days ▼ 2.0%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.19%
12-Months-Change
Fundamentals
Return on Equity
-110.89%
Trailing 12-Months
Asset Growth
4.66%
Trailing 12-Months
Company Description
Sutro Biopharma Inc
Sutro Biopharma Inc. engages in the drug discovery, development and manufacturing of pharmaceutical products. Its products technologies include XpressCF, anti-body drug conjugates, bispecifics & engineered antibodies and cGMP facility. The company was founded by James R. Swartz and Sutanto Widjaja in June 2003 and is headquartered in South San Francisco, CA.
---
STRO Stock 12 Month Forecast
Average Price Target
$10.50
▲(467.57% Upside)
Technical Analysis
Blueprint Medicines
―
Immunocore Holdings
―
Fate Therapeutics
―
RAPT Therapeutics
―
Molecular Templates
―
Voyager Therapeutics
―
Best Analysts Covering STRO
1 Year
1 Year Success Rate
3/14 ratings generated profit
1 Year Average Return
-30.72%
reiterated a buy rating 2 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 21.43% of your transactions generating a profit, with an average return of -30.72% per trade.
---